BTAI
NASDAQBioXcel Therapeutics Inc.
Website
News25/Ratings12
Price$1.08-0.76 (-41.03%)
2026-01-212026-04-24
News · 26 weeks55-57%
2025-10-262026-04-19
Mix2590d
- SEC Filings9(36%)
- Other9(36%)
- Insider4(16%)
- Offering2(8%)
- Analyst1(4%)
Latest news
25 items- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home SettingLive event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced it will host a virtual event on Thursday, April 23, from 2:00 to 3:00 p.m. ET. The event will center on the Company's ongoing launch strategy initiatives ahead of the November 14 PDUFA target action date of IGALMI® for the treatment of acute agitation associated with bipolar disorders and schizophrenia in th
- PRBioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress ReactionsDoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War Clinical Practice Guidelines for management of acute stress reactions (ASR) NEW HAVEN, Conn., April 08, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the enrollment of the first patients in a U.S. Department of War (DoW)-funded Phase 2a clinical trial evaluating BXCL501 (sublingual dexmedetomidine) for the treatment of acute stress rea
- PRBioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home SettingPDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The FDA has a
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECSEC Form S-8 filed by BioXcel Therapeutics Inc.S-8 - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECSEC Form 10-K filed by BioXcel Therapeutics Inc.10-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient SettingsNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026 Advancing commercial and launch plans based on third-party market assessment NEW HAVEN, Conn., March 27, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today reported financial results for the fourth quarter and full-year 2025 and provided an update on its late-stage pipeline and commercial launch readines
- ANALYSTRodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price targetRodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00
- INSIDERCEO and President Mehta Vimal converted options into 383 shares, increasing direct ownership by 2% to 21,259 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Financial Officer Steinhart Richard I converted options into 68 shares, increasing direct ownership by 1% to 6,645 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDEROfficer Rodriguez Javier converted options into 68 shares, increasing direct ownership by 1% to 6,863 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Scientific Officer Yocca Frank converted options into 68 shares, increasing direct ownership by 1% to 6,520 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SECSEC Form 8-K filed by BioXcel Therapeutics Inc.8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingNEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced the closing of its previously announced registered direct offering of 4,500,785 shares (the "Shares") of common stock, par value $0.001 per share ("Common Stock") (or common stock equivalents in lieu thereof), and accompanying warrants (the "Accompanying Warrants") to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per common stock equivalent in lieu thereof) and Accompanying Warrant. The Accompanying
- SECSEC Form 424B5 filed by BioXcel Therapeutics Inc.424B5 - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct OfferingNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the "Company") (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale in a registered direct offering of 4,500,785 shares (the "Shares") of common stock, par value $0.001 per share ("Common Stock") (or common stock equivalents in lieu thereof), and accompanying warrants (the "Accompanying Warrants") to purchase up to 4,500,785 shares of Common Stock at a combined offering price of $1.739 per Share (or per comm
- PRBioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid WithdrawalBXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXCL501 in opioid withdrawal Opioid use disorder is a global health crisis, affecting approximately 5.9 million adults in the U.S. NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced positive topline results from a Phase 2 investigator-sponsored trial (IST) evaluating BXCL501 for the treatment of opioid withdrawal symptom
- PRBioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's DementiaDiscussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer's dementia Large patient population affected by Alzheimer's agitation, with approximately ~100 million annual episodes1 KOL Roundtable to be held on Friday, February 27, at 2:00 p.m. EST NEW HAVEN, Conn., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced it will host a virtual key opinion leader (KOL) roundtable on Friday, February 27, from 2:00 to 3:00 p.m. EST. The event is a cont
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home SettingThird party commercial assessment shows larger than expected potential total addressable market for IGALMI® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary coverage NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the completion of an updated market opportunity assessment for IGALMI® for acute agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting, informed by results from the SERENITY At-Home clinical study
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)